Neurodegenerative Disorders: A Wealth Of Opportunities For Digital Technologies

On behalf of Allucent, Citeline conducted an online survey of subscribers who are actively engaged in neurodegenerative clinical trials and are currently working or planning to work with a CRO on these trials. The report includes data and analysis of over 100 qualified respondents representing small and mid-size biopharma companies.

How Digital Tools Are Transforming Clinical Research in Neurodegenerative Disorders

Neurodegenerative disorders are among the most complex and commercially significant challenges in drug development, driven by aging populations and rising healthcare burden. While these diseases remain largely incurable, advances in disease biology, biomarkers, technology, and therapeutic modalities such as biologics, RNA-based therapies, and cell and gene therapies, are revitalizing R&D investment and pipelines.

This research report shares insights from over 100 pharma and biotech leaders highlighting:

• Key barriers in neurodegenerative trials, including recruitment, blood–brain barrier challenges, late diagnosis, and regulatory uncertainty.
• The role of digital health, AI, and machine learning in improving trials, monitoring, and data analysis.
• The value of CRO partnerships combining neuroscience expertise, digital tools, and operational excellence.
• How integrating innovative science with digital solutions and collaboration can accelerate development and reduce patient and caregiver burden.